What it means
When a drug's patent expires, other manufacturers can sell generic versions. Regulators such as the Food and Drug Administration do not require generics to repeat the original large-scale clinical trials.
Instead, the generic maker must show bioequivalence: in studies on healthy volunteers, the generic must produce a blood-concentration profile statistically close enough to the original that patients can expect the same effect and safety. The comparison rests on two measurements.
The first is the maximum concentration the drug reaches in the blood, which captures the rate of absorption. The second is the total exposure over time, measured as the area under the concentration curve.
Regulators generally require the generic's values to fall within a confidence interval of about 80 to 125 percent of the original's, a range judged too narrow to matter clinically for most medicines. Drugs with a narrow therapeutic window, where small differences can cause harm, face tighter scrutiny.
For managers in pharma, insurance, and healthcare operations, bioequivalence is the economic gateway to generic competition. It is what allows pharmacists and insurers to substitute a cheaper generic without a new prescription, and it is why drug prices often collapse once the first generics arrive.
It also explains occasional controversies: patients who react differently after a switch may be experiencing inactive-ingredient differences or normal variability, which regulators treat as separate issues from bioequivalence itself. The standard study design is tightly specified.
Healthy volunteers take the brand product and the generic on separate occasions in random order, with a washout period between, and blood samples track concentration over time. Some drugs must also be tested after a meal, since food can change absorption.
For drugs where small differences matter clinically, regulators may tighten the acceptance band or require extra evidence, while for certain simple products, such as solutions absorbed completely, they may waive the human study altogether and accept laboratory comparisons instead.
In practice
Real-world examples.
Example
A generic manufacturer runs a crossover study where volunteers take the brand drug and the generic in sequence, and their blood measurements are compared for bioequivalence. Each volunteer serves as their own control, which removes person-to-person variation from the comparison.
Example
A hospital formulary switches to a generic antibiotic after the regulator certifies it bioequivalent, cutting the pharmacy's spending on that drug by more than half. Tender contracts increasingly require proof of bioequivalence certification before a generic can be listed.
Example
A narrow-therapeutic-index epilepsy drug is flagged for extra monitoring after generic substitution, because even small absorption differences matter more for such medicines. The prescriber checks the patient's response after the switch and the regulator may apply a tighter acceptance band to this class of drug.
Formula
Calculation
A generic is typically bioequivalent when the 90% confidence interval for the ratio of its absorption measures, maximum concentration and area under the curve, to the original's falls within 80% to 125%. The upper limit of 125% is simply the reciprocal of the lower limit, since 100 / 0.80 = 125.
Worked example. In a volunteer study the brand's average area under the curve is 200 units, and the generic's is 190 units.
- Ratio of averages = 190 / 200 = 95%.
- Suppose the 90% confidence interval for that ratio runs from 88% to 103%. Both ends sit inside the 80% to 125% band, so the generic passes on total exposure.
- If instead the interval ran from 78% to 110%, the lower end would fall below 80% and the generic would fail, even though the average ratio of 95% looks close.
- The same test is applied separately to maximum concentration, and the generic must pass both.Case study
Seen in the real world.
Fictional example: Medivance Generics spent two years developing a copy of a best-selling blood-pressure tablet. Its first formulation matched the original's total exposure but released the drug slightly faster, pushing peak concentration just outside the accepted band. The team reformulated the tablet's coating, repeated the volunteer study, and this time both measures landed within limits. Approval followed, and within six months of launch the brand's price in that market fell by 40 percent as insurers switched patients to the bioequivalent generic. Its regulatory affairs team kept both study reports on file, since tender bids for hospital contracts routinely ask for the underlying data.
Watch out
Common mistakes.
- Believing a bioequivalent generic must be chemically identical in every ingredient, when only the active ingredient and its absorption profile must match; fillers can differ.
- Assuming bioequivalence requires repeating full clinical trials, when it is established through smaller pharmacokinetic studies in volunteers.
- Reading any patient complaint after a switch as proof the generic failed bioequivalence, when variability and inactive ingredients can cause differences regulators treat separately.
Questions
People also ask.
Does bioequivalent mean identical?
No. It means the two products deliver the active ingredient at the same rate and extent within tight statistical limits. Inactive ingredients, shape, and packaging may differ.
What is the 80 to 125 percent rule?
It is the standard acceptance band: the confidence interval for the generic's absorption ratio to the original must fall within 80 to 125 percent, a range considered clinically insignificant for most drugs.
Why does bioequivalence matter for drug prices?
It lets generics win approval without repeating costly trials, enabling cheap substitutes to enter the market, which is the main reason drug prices drop after patent expiry. The band is asymmetric on a log scale, which is why the upper bound is 125 rather than 120.
From the founder's library
Take it further with the book.
Build your financial confidence beyond this definition. Shihan's full-length guide, Accounting Fundamentals, takes the same plain-English approach and turns it into a complete, practical playbook for non-finance managers, business owners and students - with chapter-end quiz answers and presentation slides included.
25% off with code MMHQ25, applied at checkout. Priced in USD - checkout may show the equivalent in your local currency.
View the book and save 25%